Development and characterization of a novel PRESAGE formulation for radiotherapy applications
β Scribed by A. Mostaar; B. Hashemi; M.H. Zahmatkesh; S.M.R. Aghamiri; S.R. Mahdavi
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 457 KB
- Volume
- 69
- Category
- Article
- ISSN
- 0969-8043
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The goal of the current study was to develop an intranasal (IN) formulation of the acetylcholinesterase inhibitor galantamine, an important therapeutic for treating Alzheimer's disease. To allow for delivering a therapeutically relevant dose, it was necessary to greatly enhance drug solubility. Vari
Our research group has successfully developed photon detectors capable of both time-stamping and energy-resolving individual photons at very high rates in a wide band from the near-IR through optical and into the near-UV. We have fabricated 32-pixel arrays of these Transition-Edge Sensor (TES) devic
1S,5R)-2-{[(4S)-azepan-4-ylamino]carbonyl}-7-oxo-2,6-diazabicyclo[3.2.0] heptane-6-sulfonic acid (Compound 1) is a b-lactamase inhibitor for intravenous administration. The objective of this preformulation study was to determine the most appropriate form of the API for development. Compound 1 can ex
The aim of this work was the characterization of a new formulation of prednisone long-term controlled release biodegradable microspheres. Poly(DL-lactide-co-glycolide) (PLGA) polymers were used for MS preparation. A S/O/W solvent evaporation method was employed for prednisone entrapment. The system